University of Sydney Professor and Rheumatology Researcher David Hunter Joins Rapid Nutrition Scientific Advisory Board
SYDNEY (Australia) – 31st August 2021, 8:00am CET - Rapid Nutrition PLC (Euronext Growth: ALRPD, OTCQB: RPNRF), a natural healthcare company focused on sports nutrition, diet management and life science products with extensive worldwide distribution, is pleased to announce the addition of David Hunter to its Advisory Board. Dr. Hunter is a professor of Medicine at the University of Sydney, where he serves as the Florance and Cope Chair of Rheumatology and Chair of Institute of Bone and Joint Research.
Ranked as the world’s leading expert in osteoarthritis on expertscape.com, Dr. Hunter has researched the effects of obesity on joint pain, making him an ideal addition to the wellness company’s board. Dr. Hunter is also a staff specialist at Royal North Shore Hospital.
“Our scientific team just gained incredible knowledge, experience and gravitas, thanks to the addition of world-renowned professor and osteoarthritis expert Dr. David Hunter,” said Rapid Nutrition CEO Simon St. Ledger. “We are thrilled to welcome him to our board and look forward to sharing his expertise and insight with consumers across the globe.”
“I am honored to connect with Rapid Nutrition, a company dedicated to developing high-quality nutrition that is backed by science,” said Dr. Hunter, who specializes in the study of arthritis and the impacts of obesity and healthy eating.
Dr. Hunter also serves on the editorial board for Arthritis and Rheumatology, Osteoarthritis and Cartilage, Arthritis Care and Research and is part of the review committee for the American College of Rheumatology, EULAR and OARSI scientific meetings. He has more than 500 peer-reviewed publications in international journals and has co-authored several books. He received the OARSI Clinical Researcher Award in 2019 as well as the Vice-Chancellor’s Award for Research Excellence and the Distinguished Professorial Achievement Award at the University of Sydney.
A native of New Zealand and an Australian citizen, he earned his Bachelor of Medicine, Bachelor of Surgery and Master of Sports Medicine at the University of New South Wales. He completed a fellowship in Rheumatology at the Royal Australian College of Physicians, and earned a Master’s of Medical Science (Clinical Epidemiology) from the University of Newcastle. He also hosts a “Joint Action” podcast, available on iTunes.
About Rapid Nutrition
Dedicated to the development and distribution of premium, science-based health and wellness brands across the globe, Rapid Nutrition shares a wealth of award-winning products with consumers who are passionate about innovations that are “made by nature, refined by science.” Rapid Nutrition’s first-class scientific team matches the experience of its management team to keep both the company and consumers on top of the latest industry trends and developments, while aligning with industry leaders worldwide to deliver effective supplements and solutions. Rapid Nutrition aims to be the supplier of choice globally by offering premium brands with the highest-quality ingredients to deliver maximum results.
For more information, please visit http://rnplc.com
Investor Relations Contact:
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and or otherwise that involve risks, uncertainties and assumptions that could cause Rapid Nutrition PLCs actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. Rapid Nutrition PLC has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Rapid Nutrition PLC undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
This media information does not constitute an offer to sell, or a solicitation of an offer to buy, any securities. This information does not constitute an offering prospectus within the meaning within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 of June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71 or a listing prospectus within the meaning of the listing rules of the Euronext Exchange or OTC Markets. The media release is in accordance with International Reporting Standard: Rule 12g3-2(b) under the Securities Exchange Act ('Rule 12g3-2(b)') permits non-U.S. companies with securities listed primarily on a Qualified Foreign Exchange to make publicly available to U.S investors in English the same information that is made publicly available in their home countries as an alternative to SEC reporting Exchange Act Rule 12g3-2(b).